Sfoglia per AUTORE
ROTA-SCALABRINI D
Collezione AOU Città della Salute di Torino

  

Items : 15

A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. in Haematologica / Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023.

2024
AOU Città della Salute di Torino

Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M;

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. in Blood cancer journal / Blood Cancer J. 2024 Jun 7;14(1):94. doi: 10.1038/s41408-024-01075-x.

2024
AOU Alessandria
AOU Città della Salute di Torino

Bruno B; Zamagni E; Stefanoni P; Palmieri S; Liberati AM; Monaco F; Annibali O; Galieni P; Garzia M; Olivero M; Rogers J; Ruggeri M; Pescosta N; Pisani F; Tosi P; Pascarella A; Pietrantuono G; Arigoni M; De Sabbata G; Bertamini L; Belotti A; Rota-Scalabrini D; D'Agostino M; Calogero RA; Boccadoro M; Musto P; Gay F;

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. in Blood / Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080.

2024
AOU Città della Salute di Torino

Paris L; Zambello R; Mancuso K; Gamberi B; Palmas AD; Gozzetti A; Cellini C; Ballanti S; Velluti C; Vincelli ID; Ronconi S; Pavone V; Grasso M; Ledda A; Oliva S; Corradini P; Morè S; Belotti A; Rota-Scalabrini D; Bertuglia G; D'Agostino M; Petrucci MT; Bruno B; Musto P; Gay F;

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F;

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. in EClinicalMedicine / EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun.

2023
AOU Città della Salute di Torino

Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; et alii...

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. in The Lancet. Oncology / Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.

2023
AOU Città della Salute di Torino

Grasso M; Zamagni E; Fioritoni F; Ballanti S; Cea M; Pescosta N; Pavone V; Ronconi S; Vincelli ID; Oddolo D; Capra A; Bertamini L; Cellini C; Gozzetti A; De Rosa L; Giuliani N; Aquino S; de Fabritiis P; Gamberi B; Palmas A; Rota-Scalabrini D; Paris L; Musto P; Mina R; Belotti A; Boccadoro M; Gay F;

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6.

2022
AOU Alessandria
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Belotti A; Tacchetti P; Fazio F; Zambello R; Luppi M; Liberati AM; Palmieri S; Annibali O; Monaco F; Galieni P; Pisani F; Capra A; Gilestro M; Curci P; Pascarella A; Tosi P; De Sabbata G; Pietrantuono G; Gentile M; Ledda A; Paris L; Morè S; Corradini P; Rota-Scalabrini D; Oliva S; Bertamini L; et alii...

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. in Blood advances / Blood Adv. 2021 Nov 9;5(21):4504-4514. doi: 10.1182/bloodadvances.2021005150.

2021
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Zinzani PL; Ciccone G; Freilone R; Rota-Scalabrini D; Zilioli VR; Botto B; Simontacchi G; Tani M; Zaja F; Abruzzese E; Rigacci L; Santoro A; Pulsoni A; Franzone P; Grapulin L; Nassi L; Frezza GP; Zanni M; Pavone V; Nardella A; Buglione M; Re A; Filippi AR; Gioia DM; Gotti M; Sacchetti GM; Evangelista A; Ricardi U; Levis M; et alii...

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. in Journal of clinical medicine / J Clin Med. 2021 Mar 11;10(6):1173. doi: 10.3390/jcm10061173.

2021
AO Ordine Mauriziano
AOU Città della Salute di Torino

Cignetti A; Aglietta M; Fagioli F; Saglietto A; Vassallo E; Gaidano V; Gammaitoni L; Sangiolo D; Frascione PMM; D'Ambrosio L; Ferrero I; Fizzotti M; Rota-Scalabrini D; Grignani G; Pessolano R; Saglio F; Gottardi D; Berger M; Salierno M; Mangioni M; Poletto S; Polo A; Paruzzo L; Becco P; Gallo S; Caravelli D; Carnevale-Schianca F;

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. in Blood / Blood. 2021 Jun 3;137(22):3027-3036. doi: 10.1182/blood.2020009507.

2021
AOU Alessandria
AOU Città della Salute di Torino

Tacchetti P; Corradini P; Caravita di Toritto T; Patriarca F; Pompa A; Monaco F; Cellini C; Rota-Scalabrini D; Antonioli E; Bernardini A; Giuliani N; Galli M; Marasca R; Tosi P; Benevolo G; Capra A; Cascavilla N; Offidani M; Gaidano G; D'Agostino M; Bonello F; Larocca A; Boccadoro M; Bringhen S;

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.

2021
AO Cuneo
AOU Città della Salute di Torino

Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. in Haematologica / Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3.

2020
ASL Torino 4
AOU Città della Salute di Torino

Boccadoro M; Larocca A; Falco P; Hájek R; Palumbo A; Marasca R; Cellini C; Petrucci MT; Tosi P; Gentile M; Baldini L; Santoro A; Aquino S; Poggiu M; Pavone V; Gazzera G; De Rosa L; Grasso M; Rota-Scalabrini D; Pezzatti S; Spada S; Ballanti S; Pescosta N; Paris L; D'Agostino M; Bringhen S;

Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation / Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec

2017
AOU Città della Salute di Torino

Sottile A; Fagioli F; Rota-Scalabrini D; Grignani G; Sangiolo D; Giraudo L; Mangioni M; Becco P; Polo A; Gammaitoni L; Gioeni L; Berger M; Fizzotti M; Nesi F; Vassallo E; D'Ambrosio L; Coha V; Gallo S; Carnevale-Schianca F; Caravelli D; Aglietta M;

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. in Blood / Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16.

2013
AOU Città della Salute di Torino
ASL Vercelli

Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A;